Abstract:Calreticulin (CRT), a luminal resident calcium-binding glycoprotein of the cell, is a tumor-associated antigen involved in tumorigenesis and also an autoantigen targeted by autoantibodies found in patients with various autoimmune diseases. We have previously shown that prokaryotically expressed recombinant murine CRT (rCRT) exhibits strong stimulatory activities against monocytes/macrophages in vitro and potent immunogenicity in vivo, which is partially attributable to self-oligomerization of soluble rCRT. However, even in oligomerized form native CRT (nCRT) isolated from mouse liver is much less active than rCRT, arguing against the possibility that self-oligomerization alone would license potent pro-inflammatory properties to nCRT. Since rCRT differs from nCRT in its lack of glycosylation, we wondered if aberrant glycosylation of eukaryotically expressed CRT (eCRT) would significantly enhance its immunological activity. In the present study, tunicamycin, an N-glycosyltransferase inhibitor, was employed to treat CHO cells (CHO-CRT) stably expressing full-length recombinant mouse CRT in secreted form for preparation of aberrantly glycosylated eCRT (tun-eCRT). Our biochemical and immunological analysis results indicate that eCRT produced by CHO-CRT cells is similar to nCRT in terms of glycosylation level, lack of self-oligomerization, relatively poor immunogenicity and weak macrophage-stimulatory activity, while tun-eCRT shows reduced glycosylation yet much enhanced ability to elicit specific humoral responses in mice and TNF-α and nitric oxide production by macrophages in vitro. Given that abberant glycosylation of proteins is a hallmark of cancer cells and also related to the development of autoimmune disorders in humans, our data may provide useful clues for better understanding of potentiating roles of dysregulated glycosylation of molecules such as CRT in tumorigenesis and autoimmunity.

Roles of calreticulin on anti-tumor effection

TRAIL and Cancer Therapy

Calreticulin Fragment 39-272 Promotes B16 Melanoma Malignancy Through Myeloid-Derived Suppressor Cells in Vivo.

Immunological Activities of Calreticulin

Calreticulin as an Adjuvant In Vivo to Promote Dendritic Cell Maturation and Enhance Antigen-Specific T Lymphocyte Responses against Melanoma

Modulation of cellular immunity by antibodies against calreticulin.

Membrane Bound CRT Fragment Accelerates Tumor Growth of Melanoma B16 Cell In Vivo through Promoting M2 Polarization via TLR4

Functional Analysis of Recombinant Calreticulin Fragment 39-272: Implications for Immunobiological Activities of Calreticulin in Health and Disease

Aberrant Glycosylation Augments the Immuno-Stimulatory Activities of Soluble Calreticulin.

Calreticulin—Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance as a Prognostic Biomarker in Ovarian Cancer Patients

Antibody-Secreting Cells under the Stimulation with Calreticulin Fragment ESEARCH ARTICLE R

Fullerenols boosting the therapeutic effect of anti-CD47 antibody to trigger robust anti-tumor immunity by inducing calreticulin exposure

Calreticulin exposure induced by anticancer drugs is associated with the p53 signaling pathway in colorectal cancer cells

Enhancement of Cancer Immunotherapy Using CRT Valgus Tumor Cell Membranes Coated Bacterial Whole Peptidoglycan Combined with Radiotherapy.

Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients

CD1dhiCD5+ B Cells Differentiate into Antibody-Secreting Cells under the Stimulation with Calreticulin Fragment

Calreticulin couples with immune checkpoints in pancreatic cancer

Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway

Reprogramming tumor microenvironment with precise photothermal therapy by calreticulin nanobody-engineered probiotics

Soluble Calreticulin Induces Tumor Necrosis Factor-Α (Tnf-Α) and Interleukin (IL)-6 Production by Macrophages Through Mitogen-Activated Protein Kinase (MAPK) and NFκB Signaling Pathways.